



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Pitavastatin Calcium (Standard)

<b>Cat. No.:</b>	HY-B0144R
<b>CAS No.:</b>	147526-32-7
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>23</sub> Ca <sub>0.5</sub> FNO <sub>4</sub>
<b>Molecular Weight:</b>	440.49
<b>Target:</b>	Mitophagy; Apoptosis; Autophagy; HMG-CoA Reductase (HMGCR)
<b>Pathway:</b>	Autophagy; Apoptosis; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC <sub>50</sub> of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects <sup>[1][2][3][8]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	HMG-CoA Reductase <sup>[1]</sup>

### REFERENCES

- [1]. Mukhtar RY, et al. Pitavastatin. *Int J Clin Pract.* 2005 Feb;59(2):239-52.
- [2]. Kajinami K, et al. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. *Cardiovasc Drug Rev.* 2003 Fall;21(3):199-215.
- [3]. Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. *Cardiovasc Drugs Ther.* 2013 Oct;27(5):413-24.
- [4]. Hamano T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. *Neurobiol Aging.* 2012 Oct;33(10):2306-20.
- [5]. de Wolf E, et al. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. *Sci Rep.* 2017 Jul 14;7(1):5410.
- [6]. Demir B, et al. The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. *Cardiovasc Ther.* 2019 May 2;2019:2549432.
- [7]. Hayashi T, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. *Atherosclerosis.* 2004 Oct;176(2):255-63.
- [8]. Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. *Prog Lipid Res.* 2021 Nov;84:101127.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA